Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.33 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.32 |
| ▸ | CDK1 | P06493 | 1/20 | 0.32 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.32 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.32 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31218768 | 1.00 | CYP11B1 (0.34) | CYP11B1CYP11B2CHRNB2CHRNA4CCNB2 | |
| SCHEMBL30392892 | 0.92 | CCNB2 (0.36) | CYP11B1CYP11B2CHRNB2CHRNA4CCNB2 | |
| SCHEMBL108593 | 0.92 | CCNB2 (0.36) | CYP11B1CYP11B2CHRNB2CHRNA4CCNB2 | |
| SCHEMBL13690850 | 0.81 | CYP11B1 (0.34) | CYP11B1CYP11B2CCNB2CDK1CCNB1 | |
| SCHEMBL9451018 | 0.75 | MEN1 (0.41) | CYP11B1CYP11B2CCNB2CDK1CCNB1 | |
| SCHEMBL511959 | 0.74 | KDM1A (0.40) | CYP11B1CYP11B2 | |
| SCHEMBL17177076 | 0.73 | CCNB2 (0.36) | CYP11B1CYP11B2CCNB2CDK1CCNB1 | |
| SCHEMBL16462321 | 0.71 | CYP11B1 (0.33) | CYP11B1CYP11B2 | |
| SCHEMBL31469673 | 0.70 | KDM4E (0.37) | — | |
| SCHEMBL1655533 | 0.70 | TRPV6 (0.42) | CYP11B2CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2426108-B1 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | METHYLGENE INC (CA) | 2016-08-10 | — | — | EP | disclosed |
| EP-2426108-B1 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | METHYLGENE INC (CA) | 2016-08-10 | — | — | EP | disclosed |
| US-9018378-B2 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | METHYLGENE INC. (CA) | 2015-04-28 | — | — | US | disclosed |
| US-9018378-B2 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | METHYLGENE INC. (CA) | 2015-04-28 | — | — | US | disclosed |
| US-9018378-B2 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | METHYLGENE INC. (CA) | 2015-04-28 | — | — | US | disclosed |
| US-8907091-B2 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | METHYLGENE INC. (CA) | 2014-12-09 | — | — | US | disclosed |
| US-8907091-B2 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | METHYLGENE INC. (CA) | 2014-12-09 | — | — | US | disclosed |
| US-8907091-B2 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | METHYLGENE INC. (CA) | 2014-12-09 | — | — | US | disclosed |
| US-20140179632-A1 | METHODS OF INHIBITING PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC. (CA) | 2014-06-26 | — | — | US | disclosed |
| US-20140179632-A1 | METHODS OF INHIBITING PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC. (CA) | 2014-06-26 | — | — | US | disclosed |
| US-20110077240-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC. (CA) | 2011-03-31 | — | — | US | disclosed |
| US-20110077240-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC. (CA) | 2011-03-31 | — | — | US | disclosed |
| EP-2262815-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | MethylGene Inc. (CA) | 2010-12-22 | — | — | EP | disclosed |
| EP-2183255-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING FUSED HETEROCYCLIC KINASE INHIBITORS | MethylGene Inc. (CA) | 2010-05-12 | — | — | EP | disclosed |
| US-20090286984-A1 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | Mirati Therapeutics, Inc. | 2009-11-19 | — | — | US | disclosed |
| US-20090286984-A1 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | Mirati Therapeutics, Inc. | 2009-11-19 | — | — | US | disclosed |
| US-20090286984-A1 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | Mirati Therapeutics, Inc. | 2009-11-19 | — | — | US | disclosed |
| WO-2009109035-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC. (CA) | 2009-09-11 | — | — | WO | disclosed |
| WO-2009026720-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING FUSED HETEROCYCLIC KINASE INHIBITORS | METHYLGENE INC. (CA) | 2009-03-05 | — | — | WO | disclosed |
| WO-2009026720-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING FUSED HETEROCYCLIC KINASE INHIBITORS | METHYLGENE INC. (CA) | 2009-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179632-A1 | METHODS OF INHIBITING PROTEIN TYROSINE KINASE ACTIVITY | PTK2B, PRKACA, DSTYK | CYP11B1 3857/4885CYP11B2 3954/4885CHRNB2 3328/4885 |
| US-20090286984-A1 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | MAP3K19, MAP3K9, MAP4K2 | CYP11B1 2331/4885CYP11B2 2753/4885CHRNB2 3838/4885 |
| US-20110077240-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | ABL1, ERBB2, TYRO3 | CYP11B1 3639/4885CYP11B2 3753/4885CHRNB2 4303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.